<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01207245</url>
  </required_header>
  <id_info>
    <org_study_id>10076</org_study_id>
    <secondary_id>NIHR RfPB PB-PG-1207-15025</secondary_id>
    <nct_id>NCT01207245</nct_id>
  </id_info>
  <brief_title>Circadian Rhythm In Tobramycin Elimination In Cystic Fibrosis</brief_title>
  <acronym>CRITIC</acronym>
  <official_title>Circadian Rhythm In Tobramycin Elimination In Cystic Fibrosis (CRITIC) A Randomized Pharmacokinetic Comparison of Tobramycin in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nottingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystic fibrosis is the most common inherited life limiting condition which affects children.&#xD;
      Patients with it develop lung infections which become difficult to clear, and damage the&#xD;
      lungs. These are treated with antibiotics (such as tobramycin) into the vein (termed&#xD;
      &quot;intravenous antibiotics&quot;). This has without doubt improved survival. However, all treatments&#xD;
      have side effects. Tobramycin can cause kidney damage. The investigators have preliminary&#xD;
      data that suggests that administering tobramycin in the morning may be safer for the kidneys&#xD;
      than administering it in the evening.&#xD;
&#xD;
      The investigators plan to approach children and adults with cystic fibrosis whose doctors&#xD;
      have decided to administer a course of intravenous tobramycin. The investigators will&#xD;
      randomly allocate them to receive it at either 0800h or 2200h. The investigators will measure&#xD;
      the rate at which the body eliminates tobramycin from the bloodstream, by measuring the&#xD;
      amount of tobramycin in the blood stream after administering the antibiotic. For each patient&#xD;
      the study will last for the duration of the course of antibiotics. This is decided by the&#xD;
      doctor looking after the patient (rather than the researcher), and would typically be 14&#xD;
      days. The investigators will also measure substances in the blood and urine (&quot;biomarkers&quot;)&#xD;
      which are sensitive indicators of low levels of kidney injury. The investigators will monitor&#xD;
      lung function and lung bacteria in both the groups to ensure that the patients in both groups&#xD;
      improve by the same amount.&#xD;
&#xD;
      If the preliminary data are proved correct, this research will allow investigators to improve&#xD;
      the safety profile of tobramycin, one of the most widely prescribed drugs in cystic fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal Elimination Rate Constant of Tobramycin</measure>
    <time_frame>Days 1, 8 and 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Day 1, 8, 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function</measure>
    <time_frame>Day 1, 8, 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Biomarkers</measure>
    <time_frame>Days 1 and 14</time_frame>
    <description>NAG, NGAL, IL-18, KIM1, Cystatin C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum biomarkers</measure>
    <time_frame>Days 1 &amp; 14</time_frame>
    <description>Serum creatinine Serum Cystatin C Estimated GFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Electrolytes</measure>
    <time_frame>Days 1 &amp; 14</time_frame>
    <description>Serum Potassium and Magnesium</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Morning dose of tobramycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of tobramycin once daily dose in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evening tobramycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Evening dose of tobramycin once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tobramycin time of administration</intervention_name>
    <description>Random allocation to time of day of administration of tobramycin</description>
    <arm_group_label>Evening tobramycin</arm_group_label>
    <arm_group_label>Morning dose of tobramycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of cystic fibrosis (CF) (defined as clinical features of CF plus a positive&#xD;
             sweat test OR the presence of 2 genes known to be associated with CF disease)&#xD;
&#xD;
          -  Males or female 5 years and older&#xD;
&#xD;
          -  Treating doctor has decided to commence a course of tobramycin&#xD;
&#xD;
          -  Patient or parent / legal guardian able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous episode of acute kidney injury&#xD;
&#xD;
          -  Solid organ transplantation&#xD;
&#xD;
          -  Evidence of impaired renal function (raised serum creatinine above the normal range&#xD;
             for age)&#xD;
&#xD;
          -  Once daily aminoglycoside unsuitable because of hypersensitivity or previous high&#xD;
             trough levels on once daily dosing.&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Smyth</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nottingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>September 21, 2010</study_first_submitted>
  <study_first_submitted_qc>September 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2010</study_first_posted>
  <last_update_submitted>June 22, 2015</last_update_submitted>
  <last_update_submitted_qc>June 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic fibrosis</keyword>
  <keyword>Tobramycin</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

